Related Experiment Video
Updated: Oct 4, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
[Prostate-specific membrane antigen positron emission tomography (PSMA PET) for urologists-when and which tracer?]
Christoph Berliner1, Claudia Kesch2, Wolfgang P Fendler3
1Klinik für Nuklearmedizin, Universitätsklinikum Essen, Hufelandstr. 55, 45147, Essen, Deutschland. christoph.berliner@uk-essen.de.
Background:
Prostate-specific membrane antigen positron emission tomography (PSMA PET) is increasingly replacing conventional imaging for staging of prostate cancer. A major challenge is its appropriate use and correct interpretation.
Objectives:
How and when is PSMA PET used in patient care to optimally direct therapy?
Materials And Methods:
Systematic presentation and discussion of the current state of knowledge, guidelines and expert knowledge on PSMA PET with a summary of ongoing studies.
Conclusion:
PSMA PET is the new standard for systemic staging of prostate cancer, enabling precision patient care with novel local, oligometastatic, and systemic treatment approaches.
More Related Videos
09:49A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
Published on: April 24, 2020
06:08A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
Published on: March 21, 2025
Related Concept Videos
Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET
Imaging Studies IV: Magnetic Resonance Imaging